Imaging in clinical trials isn’t optional anymore; it’s foundational. In GLP-1 and neurology trials, where ocular endpoint sensitivity is everything, the quality and timing of imaging can directly...
Read More
At ARVO 2025, one truth cut through the noise: you can’t innovate at the expense of data integrity. As trials evolve to be more decentralized and patient-centric, the pressure to maintain precision,...
Read More
When planning a clinical trial, there's a tendency to focus on enrollment—building lists, recruiting participants, and getting sites up and running quickly. While this is important to hit deadlines...
Read More
Key Takeaways: Early engagement with imaging vendors during protocol development can prevent costly delays and amendments Preclinical imaging data should inform clinical trial design, especially for...
Read More
Clinical trials are evolving rapidly. Driven by technological advancements, there is a pressing need to make studies more patient-centric. The term Decentralized Clinical Trials (DCTs) has gained...
Read More
Ophthalmic assessments are no longer mere box-checks in clinical trials. With advanced imaging and endpoints becoming the norm, sponsors must grapple with complexity and risk that extend well beyond...
Read More
For many sponsors, the full meaning of “ophthalmic assessments” might remain an afterthought until those requirements start complicating site setup, timelines, budget, or patient enrollment. Yet...
Read More
Recent research analyzing over 424,000 patients has revealed an association between semaglutide—a widely used medication for type 2 diabetes and weight management—and an increased risk of developing...
Read More